Table 2.
The relationships between lncRNAs and the hallmarks of gastric cancer
| Function | LncRNA | Expression | Target | Reference |
|---|---|---|---|---|
| LncRNAs and proliferation | Linc00152 | up | EGFR | 99 |
| AK123072 | up | EGFR | 100 | |
| ZFPM2-AS1 | up | MIF/P53 | 104 | |
| OnclncRNA-626 | up | SRSF1/p53 | 107 | |
| GAS5 | up | eIF4A3/P53 | 147 | |
| PWRN1 | down | miR-425-5p/PTEN/Akt/MDM2/p53 | 148 | |
| AK023391 | up | PI3K/Akt/p53 | 149 | |
| TUBA4B | down | miR-214 and miR-216a/b /PTEN | 109 | |
| LINC00470 | up | METTL3/PTEN | 110 | |
| PCAT-1 | up | EZH2/PTEN | 150 | |
| Linc00441 | up | RB1 | 77 | |
| MEG3 | up | P53,RB | 151 | |
| BC032469 | up | BC032469/miR-1207-5p/hTERT | 90 | |
| LncRNAs and resistance to cell death | XIAP-AS1 | up | XIAP | 118 |
| TINCR | up | KLF2 | 121 | |
| LINC01419 | up | PI3K/Akt1/mTOR | 124 | |
| HAGLROS | up | miR-100-5p/mTOR ,mTORC | 152 | |
| LncRNAs and metastasis | MAGI2-AS3 | up | MAGI2-AS3/miR-141/200a/ZEB1 | 128 |
| DLX6-AS1 | up | miR-204-5p/OCT1 | 130 | |
| HULC | up | miR-9-5p/MYH9 | 153 | |
| DLX6-AS1 | up | FUS-regulated MAP4K1 | 154 | |
| SNHG16 | up | DKK3 | 155 | |
| ELIT-1 | up | TGFβ/Smad3 signaling | 156 | |
| LINC01133 | up | miR-106a-3p/APC | 81 | |
| MEG3 | down | E-cadherin,Vimentin | 157 | |
| LncRNA-ATB | up | MiR‐141‐3p/TGFβ2 | 158 | |
| LINC00675 | down | vimentin | 159 | |
| SNAI1 | up | CDH1 | 160 | |
| LncRNAs and DNA damage | PANDAR | up | NFYA, p53/CDKN1A | 134 |
| NORAD | up | miR-608 | 136 | |
| LncRNAs and angiogenesis | PVT1 | up | STAT3/VEGFA | 139 |
| LINC01314 | down | KLK4 | 140 | |
| ZEB2-AS1 | up | Wnt/β-catenin pathway | 161 | |
| MEG3 | down | MEG3/miR-21 | 162 | |
| LncRNAs and the immune response | UCA1 | up | miR-193a, miR-214/PDL1 | 80 |
| LncRNAs and the stemness of GC | LOXL1-AS1 | up | LOXL1-AS1/miR-708-5p/SOX2 | 145 |
| SPRY4-IT1 | up | SPRY4-IT1/miR-101-3p/AMPK | 146 | |
| MACC1-AS1 | up | MACC1-AS1/miR-145-5p | 163 | |
| MALAT1 | up | SOX2 mRNA | 164 |